Ionis Pharmaceuticals, Inc.

Today we announced a new update to our Board of Directors. Read the full press release: https://bit.ly/3RXkCwu

In May, Ions across the country joined families, caregivers and advocates to celebrate and support the Angelman syndrome (#AS) community. It was an honor to meet, reconnect with and learn from so many wonderful people to raise awareness and drive progress. Thank you to Angelman Syndrome Foundation and everyone who turned out to rally behind this incredible community.  #AngelmanStrong #IONISimpact

This month, we are presenting new analyses from our Phase 3 studies of our investigational treatment for severe hypertriglyceridemia (#sHTG) at #ADASciSessions, #NLASessions and #ENDO2026. We look forward to sharing these results with the medical community. Read more: https://bit.ly/4dP6PAF

Last call for proposals: We’re pleased to support academic investigators advancing innovative strategies to enhance the kinetic on-rate of antisense oligonucleotides within the cellular environment. Bold and original ideas will be funded for up to two years. Interested in submitting a proposal? White papers are due July 1, 2026. Learn more: https://bit.ly/4tA3gDC #IONISinnovation

Today, with our partner GSK, we announced positive results from two Phase 3 studies for an investigational medicine for the treatment of chronic hepatitis B (CHB), presented at #EASLCongress 2026.    Learn more: https://lnkd.in/ew_V9SYp EASL | The Home of Hepatology

The Eastern Allergy Conference Conference brings together allergists, immunologists and industry leaders focused on advancing care for people living with serious diseases, including hereditary angioedema (#HAE).   Ionis is in Palm Beach this week sharing insights on our RNA-targeted technology and ongoing work to advance innovation in HAE. https://bit.ly/4dHHvLJ

Ever wonder what it’s like to work in manufacturing at a biotech? Evan, a senior research associate in Manufacturing and Operations, is here to answer your questions about landing a technical role you love, life at Ionis and making an impact on a team committed to quality and efficiency.    Drop your questions in the comment section and stay tuned for Evan’s responses, coming soon. #IONIScareers

On #ClinicalTrialsDay, we recognize the patients, caregivers and families who make innovation possible. Every trial participant plays a critical role in advancing investigational medicines to bring new treatment options closer to people who need them the most.     Your willingness to step forward leads to new discoveries and new hope. To all trial participants everywhere: thank you.  #CTD2026 #IONISimpact

Hereditary angioedema (#HAE) is a rare genetic condition that causes sudden, unpredictable episodes of severe swelling.    Even with treatment, many face ongoing attacks that take a heavy physical and emotional toll. It’s a continuous fight where daily decisions are often dictated by the “what ifs.”    This #HAEDay, we recognize the lived experiences behind the data and reaffirm our commitment to supporting the HAE community. Explore resources here: https://bit.ly/3P3f0zW

Team Ionis is getting #active4HAE in support of HAE Day, an annual observance on May 16 to raise awareness of hereditary angioedema (HAE) worldwide.    HAE is a genetic #raredisease characterized by unpredictable and potentially painful swelling of the skin, gastrointestinal (GI) tract, upper respiratory system, face and throat.     We’re proud to support HAE International (HAEi) with the goal of creating an environment for earlier and more accurate diagnosis to secure better quality of life for everyone with HAE.    Learn more and sign up for the challenge at https://haeday.org/ to make your activity count through May!